ReviewVaccines2021
Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions.Vaccines · 2026Review
- Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions.Vaccines · 2026Review
- Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.Discover oncology · 2024Review
- Dendritic Cells in Cancer Immunology and Immunotherapy.Cancers · 2024Review
- First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).Journal for immunotherapy of cancer · 2023Article
- mRNA-From COVID-19 Treatment to Cancer Immunotherapy.Biomedicines · 2023Review
- Current status and progress of the development of prostate cancer vaccines.Journal of Cancer · 2023Review
- Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.Cells · 2022Review
- Anti-cancer peptide-based therapeutic strategies in solid tumors.Cellular & molecular biology letters · 2022Article
- Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials.Molecular therapy oncolytics · 2022Review
- Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?International journal of molecular sciences · 2022Review
- Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.Biomedicines · 2022Review
- Biomimetic nanoparticles for tumor immunotherapy.Frontiers in bioengineering and biotechnology · 2022Review
- Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study.Frontiers in immunology · 2022Article
- Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer.Scientific reports · 2021Article
- DNA Methylation Modification Regulator-Mediated Molecular Clusters and Tumor Metabolic Characterization in Prostate Cancer.Journal of oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the last years, many new treatment options have widened the therapeutic scenario of genitourinary malignancies. Immunotherapy has shown efficacy, especially in the urothelial and renal cell carcinomas, with no particular relevance in prostate cancer. However, despite the use of immune checkpoint inhibitors, there is still high morbidity and mortality among these neoplasms. Cancer vaccines represent another way to activate the immune system. We sought to summarize the most recent advances in vaccine therapy for genitourinary malignancies with this review.
methodsWe searched PubMed, Embase and Cochrane Database for clinical trials conducted in the last ten years, focusing on cancer vaccines in the prostate, urothelial and renal cancer.
resultsVarious therapeutic vaccines, including DNA-based, RNA-based, peptide-based, dendritic cells, viral vectors and modified tumor cells, have been demonstrated to induce specific immune responses in a variable percentage of patients. However, these responses rarely corresponded to significant survival improvements.
conclusionsFurther preclinical and clinical studies will improve the knowledge about cancer vaccines in genitourinary malignancies to optimize dosage, select targets with a driver role for tumor development and growth, and finally overcome resistance mechanisms. Combination strategies represent possibly more effective and long-lasting treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.